Categories: Science

Dalhousie University's Institute for Research in Materials expands reach

Dalhousie University’s Institute for Research and Materials (IRM) in Halifax is expanding the scope of its ambition by reaching out to early-stage venture funds like Innovacorp, the Atlantic Canadian Opportunities Agency (ACOA) and investors across Canada under the new leadership of Dr. Daniel Boyd, who was appointed IRM director last summer.
“We don’t need evolutionary change in materials design; we need revolutionary change to satisfy the requirements of the 21st century,” said Dr. Boyd to the Dalhousie News.
Now in its 14th year, the IRM works with seven faculties, 16 departments and over 90 faculty members across the university, but if Dr. Boyd gets his way, the research group will be reaching out much further in the coming year beyond the confines of Dalhousie.
Boyd has already solicited input from a variety of stakeholders to develop a five-year plan to develop the school into a world leader in materials research.
“When I think about IRM, I just think opportunity, opportunity, opportunity,” says Dr. Boyd. “It’s an opportunity to put Dal on the map, not just regionally and nationally, but internationally, by tackling some of these big scientific challenges that have been identified around the world.”
Over the past few years, research conducted by the IRM brought in about $40 million, broken down into three key application areas: energy and sustainability ($18 million), resources and advanced manufacturing ($16 million), and health and life sciences ($7 million).
Dr. Boyd spent his first few months in the job working with the vice-president research’s office to evaluate the past five years’ IRM activities and see if they were in line with international trends in materials research, along the lines of strategic objectives regarding materials as spelled out by the European Union and the U.S. National Science Foundation.
Having previously worked in the private sector, helping to launch two start-up firms including Covina Biomedical, that worked with material research that came out of Dalhousie labs, Dr. Boyd sees the potential for linkages between enterprise, government and academia for research opportunities that are going to change how we think of the material world in the 21st century.
Materials that came out of research conducted at the IRM include an injectable glass material used for treating spinal injuries, used by Covina Medical, a battery testing system that allows companies to develop longer lasting cells, used by Novonix, and a process for producing natural materials that heal diabetic ulcers, used by DeCell Technologies.
The objective of Dr. Boyd’s five-year plan will be to reinforce those alliances with the private sector and create new opportunities for research, development and commercialization of advanced materials research produced by the IRM.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: dalhousie university
Terry Dawes

Recent Posts

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

4 hours ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

4 hours ago

Is GOOGL still a buy?

Following a widely applauded first quarter beat, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Alphabet (Alphabet… [Read More]

1 day ago

NLH has 173% upside, Echelon says

Following an acquisition, Echelon Capital Markets analyst Stefan Quenneville has maintained his "Buy" rating on Nova Leap Health (Nova Leap… [Read More]

1 day ago

Shopify upgraded to “Buy” at Citi

The stock has been flat since November, but Citi analyst Tyler Radke thinks there is now money to be made… [Read More]

1 day ago

Sabio has 400% upside, Eight Capital says

Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]

4 days ago